The Good, the Bad and the Wrinkly
Protocol M24-724 is a new Open-label Study to Evaluate Subject Satisfaction with the Overall Face and Neck Appearance After Combined Treatment with Abbvie approved aesthetic products. Only subjects with Moderate or severe submental fat will receive this product.
What is KYBELLA?
The newest collaboration/acquisitions for this pillar includes FutureGen for ABBV-701 along with 3 prior acquisitions in 2024 including Celsius for ABBV-8736, Landos for ABBV-113 and Createrna for ABBV-848.
What is Immunology?
Transition for this compound was completed on 31 Jul 2024. AbbVie VVS is the global safety database for this compound from 01 Aug 2024 onwards.
What is ABBV-CLS-7262?
On 16-Oct-2024, U.S. FDA approved this compound as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with Advanced Parkinson's Disease (PD).
What is Vyalev (foscarbidopa/foslevodopa)?
This global iconic literally amazing ISSO team has handled multiple acquisitions, new product indications, RSI oversight, initiatives including case quality, and data collection all while keeping an eye on our products and keeping us safe.
SOPROL!
The newest indication for BOTOX® Cosmetic (onabotulinumtoxinA) FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck.
What are "Platysma Bands"?
The product Elahere (mirvetuximab soravtansine) came with the acquisition of this company.
What is Immunogen?
Collaborative work on this ISSO 2024 Priority began early in the year for the Immunology pillar along with our Patient Services group in an effort to reduce non-Qualifiable cases entering the workflow by 10%.
What is the PSP Reimagine Project
This Heme-Onc product received approval of its second indication, Follicular Lymphoma, in 2024.
What is Epkinly (epcoritamab)?